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Abstract
Background: A repeat dose of Gonadotropin-releasing Hormone (GnRH) agonist could
provide long duration of luteinizing hormone (LH) surge and amplitude appropriately.
Objective: Improvement in oocyte maturity could be obtained by a repeat dose of
GnRH agonist.
Materials and Methods: In this randomized double-blinded study, 120 women with
polycystic ovarian syndrome and serumestradiol level (E2)> 3000whowere candidate
for in vitro fertilization with Antagonist protocol were enrolled between July 2018 and
July 2019. Participants were randomized in two groups - and final oocyte maturation
was triggered with two doses: In group A, a repeat dose of 0.1 mg, 12 hr. after the first
dose and in group B, 0.2 mg SC triptorelin (decapeptyl) 35 hr. prior to oocyte retrieval.
Serum Estradiol, LH, and progesterone concentration were measured on the trigger
day. Serum LHmeasurement was done three times in both groups. The outcomes were
oocyte yield, meiosis (M) I, MII, Maturity rate, germinal vesicle (GV) rate, 2 pronuclear,
embryo yield, ovarian hyper stimulation syndrome rates.
Results: Maturity rate (p = 0.89), MI (p = 0.38), MII (p = 0.89), and GV oocytes (p = 0.38)
were not statistically different between the two study groups. LH levels measured at 12
hr post-trigger did not relate statistically significant with maturity rate in our participants
(p = 0.96). No empty follicular syndrome was reported.
Conclusion: Although, the second dose of GnRH agonist after 12 hr since the first dose
could provide duration of LH surge and amplitude and as a result no empty follicular
syndrome was seen, the maturity rate, MI, MII, and GV oocytes were not different
between the two study groups.
Key words: Polycystic ovarian syndrome, Treatment, In vitro fertilization,
Gonadotropin-Releasing hormone.
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1. Introduction
Gonadotropin-releasing hormone agonists
(GnRHa) were introduced in 1990s for final oocyte
maturation in in vitro fertilization (IVF) cycles
as an alternative to standard human chorionic
gonadotropin (HCG) in GnRH antagonist protocol
(1, 2). GnRHa trigger is the cause of FSH surge
that moves up nuclear maturation (3, 4). HCG
with a big carbohydrate content has a luteinizing
hormone (LH) like activity with long half-life and
persistent LH receptor activity (5); in contrast with
HCG, GnRH agonist induces surge of both LH and
FSH and has shorter activity that result in notable
decrease in the risk of ovarian hyperstimulation
syndrome (OHSS) (6, 7). LH surge in natural
cycle continues for 48 hr and is divided into
three phases: quickly ascension phase, plateau
phase that continues for 14 hr, and decreasing
phase of 20 hr (8). The LH surge result from the
GnRHa trigger included in two phases: small
ascending arm (4 hr) and prolonged decreasing
arm (20 hr); therefore, decreasing OHSS syndrome
attributed to inadequate LH surge (9). On the
other hand, empty follicular syndrome (EFS) and
immature oocyte syndrome cases were also
reported after the GnRHa prescription, which
questions the single dose GnRHa efficacy (10,
11).
In addition, in PCOS women and hyper
responders after GnRHa trigger, the gonadotropin
answer is greatly shorter than endogenic LH surge
in a natural cycle that causes more suboptimal
expected answer (12, 13). The underlying
mechanisms proposed are that some women
with PCOS show neuro-endocrine abnormalities;
moreover, the supraphysiologic estradiol (E2)
level cause apparent increase in the number of
follicles and insufficient number of LH receptor
(14), therefore, a single dose of GnRHa might
not lead to LH surge over a threshold level in
these participants. In order to gain optimum
responses, repeated dose 12 hr after starting
doses of GnRHa resulted in terms of better
maturity of oocytes, higher number of blastocysts,
and higher clinical pregnancy in Deepikaand
colleagues study. In a similar research, we
aimed to evaluate if a second dose 12 hr. after
the first dose of GnRH agonist trigger could
provide long duration of LH surge and amplitude
appropriately making an improvement in oocyte
maturity.
The aim of this study was to see weather oocyte
maturity will improve by a repeat dose of GnRHa or
not?
2. Materials and Methods
This study is a prospective, randomized double-
blind study conducted at Research and Clinical
Center for Infertility. All women identified with
PCOSwere enrolled in this study and IVF was done
for them in antagonist protocol between July 2018
and July 2019.
The inclusion criteria were 1) PCOS women
outlined based on ESHREASRMRotterdam criteria,
2) stimulation in a GnRH ant protocol, 3) age 20-38
yr, 4) E2 concentration > 3000 IU on trigger day,
5) Body Mass Index > 18 and < 30, 6) indication for
IVF, and 7) participants’ desire
The exclusion criteria were 1) severe male factor,
2) uterine abnormally, 3) endometriosis, and 4)
metabolic disease (ex. Diabetes).
2.1. Study protocol
In PCOS women, controlled ovarian stimulation
was started with recombinant FSH (Gonal-f, Merck
Serono, Germany) at the dosage of 150 IU/day,
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beginning day 2 of the cycle. GnRH antagonist-
Ganirelix (Orgalotran) 0.25 mg/day subcutaneous
(sc) was started in flexible protocol when at least
one follicle was > 14 mm. Gonadotropin and
antagonist were continued until the trigger day.
Follicular development was probed by transvaginal
sonography.
Serum E2, LH, and progesterone concentration
were measured on the trigger day when three lead
follicles reached 17 mm in diameter. Participants
with serum E2 > 3000 based on randomization
table number were divided in two groups. Final
oocyte maturation was triggered with a single
dose of 0.2 mg sc triptorelin (decapeptyl) 34-36
hr. prior to oocyte retrieval in both groups. In
group A, a repeat dose of 0.1 mg, 12 hr after
the first dose was prescribed, but in group B,
a single dose of GnRHa 0.2 mg sc triptorelin
(decapeptyl) was given. In group A, serum LH was
measured 12 hr. after the first dose of GnRHa
administration, and then again after the second
dose of GnRHa and prior to oocyte retrieval.
In group B also, serum LH measurement was
measured three times as group A. Transvaginal
ultrasound guided oocyte pickup (OPU) was
done 35 hr after the first dose agonist. Oocyte
retrieval was done under general anesthesia with
single lumen oocyte retrieval needle (Swemed,
Vitrolife, Sweden). OHSS symptom assessment and
transvaginal sonography was done on days 4 and 7
post pick-up to evaluate the ovarian size, free fluid
in Douglas. IVF or intracytoplasmic sperm injection
was done based on sperm parameter. Fertilization
was assessed 18 hr. following IVFwith the presence
of 2 pronuclei (2PN).
The outcomes were oocyte yield, MI rate,
MII rate, maturity rate, germinal vesicle (GV)
rate, 2PN, and embryo yield OHSS rates and
type were also assessed. Maturity rate was
defined as the ratio of MII oocytes (presence
of a polar body) to the total number of
oocytes. Serum LH (IU/L), E2, and Progesterone
(ng/mL) levels were compared between the
two groups. All good-quality embryos were
frozen.
2.2. Ethical consideration
Signed informed consent was obtained from all
participants before enrollment. The study protocol
was approved by Shahid Sadoughi University
of Medical Science ethical committee (code:
IR.SSU.RSI.1397.022).
2.3. Statistical analysis
Data were analyzed with the Statistical Package
for the Social Sciences, version 20.0 (SPSS, USA).
Independent sample t test was used for continuous
variables that were normally distributed and Mann-
Whitney U-test for non-normally distributed data.
The significant level of p-value was considered P
< 0.05.
3. Results
120 participants were enrolled in the study; 30
were excluded because of the exclusion criteria
and missing follow-up. The patients characteristics
in both groups A and B are presented in Table I.
The consort flow diagram is presented as Figure
1. The percentage of mild and moderate types
of OHSS were 23.5% and 76.5%, respectively,
in group A, and mild, moderate, and severe
OHSS were 29.6%, 66.7%, and 3.7%, respectively,
in group B. The outcomes are presented in
Table II. As presented in Table II, no variable
was statistically different between the two
groups.
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Table I. Comparison of patients characteristics between group A and group B
Variables Group A (n = 49) Group B (n = 41) p-value
Age 29.30 ± 4.15 28.95 ± 5.23 0.72*
BMI 22.29 ± 4.03 22.27 ± 4.14 0.98*
Duration of infertility 6.32 ± 3.11 5.42 ± 3.18 1.8*
Primary infertility N (%) 43 (87.8) 35 (85.4)
Secondary infertility 6 (12.2) 6 (14.6)
0.74*
OHSS 34 (69.4) 27 (65.9) 0.72*
AMH 8.68 ± 3.92 7.48 ± 3.81 0.14*
Estradiol 6543.22 ± 588.76 4912.16 ± 333.41 0.04**
Progesterone 1.17 ± 0 .15 1.11 ± 0.17 0.86**
LH1 2.08 ± 0.22 3.02 ± 0.36 0.03**
Data presented as Mean±SD
BMI: Body mass index; OHSS: Ovarian hyper stimulation syndrome; AMH: Anti Mulerian hormone; LH: Luteinizing hormone;
Independent sample t test*, Mann-Whitney U-test**
Table II. Comparison of outcomes between group A and group B
Variables Group A (n = 49) Group B (n = 41) p-value
Maturity rate 0.80 ± 0.21 0.79 ± 0.18 0.89*
Oocyte number
MI 1.28 ± 0.28 1.62 ± 0.54 0.38**
MII 19.83 ± 1.17 15.02 ± 1.10 0.06**
GV 3.02 ± 0.55 1.72 ± 0.27 0.38**
ART method
IVF 6.89 ± 9.37 5.00 ± 6.66 0.28*
ICSI 12.85 ± 7.20 10.41 ± 5.63 0.08*
2PN 10.93 ± 7.29 9.46 ± 6.60 0.32*
Embryo 9.95 ± 7.23 8.51 ± 5.48 0.29*
LH2 50.29 ± 29.19 50.60 ± 35.21 0.96*
LH3 15.75 ± 9.77 15.60 ± 11.25 0.94*
LH4 4.71 ± 0.43 6.10 ± 1.11 0.66**
Data presented as Mean±SD
MI: Meiosis I; MII: Meiosis II; GV: Germinal vesicle; IVF: In vitro fertilization; ICSI: Intra cytoplasmic sperm injection; 2PN 2
pronuclear; LH: Luteinizing hormone; Independent sample t test*, Mann-Whitney U-test**
Assessed for eligibility (n = 120)
Excluded (n = 8)
● Not meeting inclusion criteria (n = 5)
● Declined to participate (n = 3)
Enrollment
Randomized (n = 112)
Group B (n = 56)
● Received a single dose of GnRHa 0.2 mg sc
triptorelin (decapeptyl)
Allocation
Group A (n = 56)
● Received a repeat dose of 0.1 mg, 12 hr after
the first dose of GnRHa 0.2 mg sc triptorelin 
(decapeptyl)
Lost to follow-up (n = 12)
Declined to participate
Follow-up
Lost to follow-up (n = 5)
Declined to participate
Analyzed (n = 41)
● Excluded from analysis (n = 3)
Analysis
Analyzed (n = 49)
● Excluded from analysis (n = 2)
Figure 1. Consort flow diagram.
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4. Discussion
Oure results showed that the maturity rate,
MI, MII, and GV oocytes were not statistically
different between the two study groups. LH
levels measured at 12 hr. post-trigger did not
relate statistically significant with maturity rate
in our participants also no empty follicular
syndrome was reported. It is identified that
the restart of meiosis at 18 hr. after the onset
of LH surge (15), and for the highest oocyte
maturation, LH concentration should be retained
over a threshold for 14-27 hr. A shorter duration
and low-level LH concentration post-trigger
with single dose of GnRHa cannot maintain
an LH level over threshold for 14-27 hr, thus
insufficient to induce best oocyte maturation. This
suboptimal response can be more probable in
women with PCOS, a condition with hypothalamic-
pituitary-ovarian axis dysfunction. Deepika and
colleagues claimed a repeat dose of GnRHa
at this critical hour (12 hr) could preserve the
amplitude and the duration of gonadotropin
surge, thus optimizing the oocyte maturity (16).
They obtained a significantly higher yield of MII
oocytes along with a statistically significant
lesser number of MIs and GV oocytes in
the repeat dose group. Our study findings
do not support these findings. In our study,
maturity rate, MI, MII, and GV oocytes were
not statistically different between the two
study groups, which question the proposed
mechanism in repeat dose protocol. Moreover,
the LH levels measured at 12 hr post-trigger
predicted oocyte maturity in Deepika and
colleagues study (16). But this relationship was
not approved in our analysis. So, we can say
that LH level post-trigger cannot necessarily
predict the oocyte maturity and so the second
dose does not improve the outcome of oocyte
maturity.
EFS is a complication of IVF. It’s thwarting
for participants and leads to cycle cancelation.
The etiopathophysiology of EFS is still unknown.
It is reported as a complication in single-dose
GnRHa trigger. Pituitary gland is the location
of action for GnRHa and dysfunctions of the
hypothalamic-pituitary-ovarian axis might not make
optimal flare leading to deficient final oocyte
maturation and EFS (17). We proposed that a
second dose of GnRH agonist after 12 hr. since
the first dose could provide duration of surge and
amplitude and as a result of that may improve
oocyte maturity after the GnRHa trigger. In our
participants, no EFS was reported to support our
hypothesis.
4.1. Limitation
Our study had some limitations such as small
sample size and missing reproductive outcomes.
Overall, although one previous study with a proof-
of-concept RCT suggested that a repeat dose of
GnRHa 12 hr following the first dose in PCOS
undergoing IVF delivers a better cycle outcome
in terms of maturity of oocytes, higher number of
blastocysts, and clinical pregnancy improvement,
our RCT study revealed no difference between
the repeat-dose and single-dose GnRHa trigger.
Therefore, more RCT studies with large sample size
and long follow-up is needed to evaluate the repeat
dose effect more precisely.
5. Conclusion
Although, the second dose of GnRH agonist
after 12 hr since the first dose could provide
duration of LH surge and amplitude and as a
result no empty follicular syndrome was seen, the
maturity rate, MI, MII, and GV oocytes were not
different between the two study groups.
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